open access

Ahead of Print
Case report
Published online: 2021-05-07
Submitted: 2020-07-20
Accepted: 2020-11-20
Get Citation

Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient

Katsunori Kagohashi, Kunihiko Miyazaki, Toshihiro Shiozawa, Hiroaki Satoh
DOI: 10.5603/ARM.a2021.0016

open access

Ahead of Print
CASE REPORTS
Published online: 2021-05-07
Submitted: 2020-07-20
Accepted: 2020-11-20

Abstract

Rechallenge of immune checkpoint inhibitors (ICPIs) is one of the attractive but unestablished treatment for recurrent non-small cell lung cancer (NSCLC) patients who have been treated with several-lines of systemic chemotherapy. In some NSCLC patients, effects of ICPI rechallenge therapy have become apparent. In ICPI treatment, although very rare, a phenomenon called pseudoprogression is known. We report the first case of a patient who had pseudoprogression during successful rechallenge of ICPI in a NSCLC patient. Although not fully clarified, factors related to the onset of pseudoprogression and good response to ICPI rechallenge are being investigated. Our case showed that pseudoprogression could be developed even in patients with ICPI rechallenge therapy.

Abstract

Rechallenge of immune checkpoint inhibitors (ICPIs) is one of the attractive but unestablished treatment for recurrent non-small cell lung cancer (NSCLC) patients who have been treated with several-lines of systemic chemotherapy. In some NSCLC patients, effects of ICPI rechallenge therapy have become apparent. In ICPI treatment, although very rare, a phenomenon called pseudoprogression is known. We report the first case of a patient who had pseudoprogression during successful rechallenge of ICPI in a NSCLC patient. Although not fully clarified, factors related to the onset of pseudoprogression and good response to ICPI rechallenge are being investigated. Our case showed that pseudoprogression could be developed even in patients with ICPI rechallenge therapy.

Get Citation

Keywords

rechallenge; immune checkpoint inhibitor; pseudoprogression; non-small cell lung cancer

About this article
Title

Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient

Journal

Advances in Respiratory Medicine

Issue

Ahead of Print

Article type

Case report

Published online

2021-05-07

DOI

10.5603/ARM.a2021.0016

Keywords

rechallenge
immune checkpoint inhibitor
pseudoprogression
non-small cell lung cancer

Authors

Katsunori Kagohashi
Kunihiko Miyazaki
Toshihiro Shiozawa
Hiroaki Satoh

References (15)
  1. Remon J, Passiglia F, Ahn MJ, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol. 2020; 15(6): 914–947.
  2. Giaj Levra M, Cotté FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 2020; 140: 99–106.
  3. Hirano S, Hayama N, Tabeta H, et al. Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment. J Thorac Oncol. 2020; 15(1): e20–e22.
  4. Watanabe H, Kubo T, Ninomiya K, et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol. 2019; 49(8): 762–765.
  5. Fujita K, Uchida N, Yamamoto Y, et al. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Anticancer Res. 2019; 39(7): 3917–3921.
  6. Niki M, Nakaya A, Kurata T, et al. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget. 2018; 9(64): 32298–32304.
  7. Blasig H, Bender C, Hassel JC, et al. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res. 2017; 27(4): 321–325.
  8. Seymour L, Bogaerts J, Perrone A, et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3): e143–e152.
  9. Liang H, Xu Y, Chen M, et al. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer. 2020; 11(4): 1068–1075.
  10. Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. J Thorac Oncol. 2019; 14(3): 468–474.
  11. Martin-Romano P, Castanon E, Ammari S, et al. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Med. 2020; 9(8): 2643–2652.
  12. Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 Suppl 4(Suppl 4): iv192–iv237.
  13. ACCN clinical practice guideline in oncology; Non-small cell lung cancer. Version 2. 2018-December 19, 2917 https://www2.tri kobe.org/nccn/guideline/lung/english/non_small.pdf.
  14. Failing JJ, Dudek OA, Marin Acevedo JA, et al. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. Future Oncol. 2019; 15(22): 2645–2656.
  15. Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017; 28(5): 1130–1136.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl